Rgenta Therapeutics, Inc.
Other Technology
On its website, the company describes its work as “Rgenta analyzes vast genomic data with proprietary methods to pinpoint interactions of the splicing machinery and RNA best suited for small molecule binding, designing and…”.
Research Rgenta Therapeutics, Inc.
Tracking coverage
Some source history is available; coverage remains limited.
- Momentum +1 · Limited coverage
- The latest public index does not report a rank for this company.Index checked:
- Fundraising +2 · Limited coverage
- Verified filings recorded. Existing baseline history earns no points.SEC source checked:
- New VC +3 · Awaiting data
- No verified dated source evidence recorded.
- Completed exit +10 · Awaiting data
- Exit news coverage has not started.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
What it does
On its website, the company describes its work as “Rgenta analyzes vast genomic data with proprietary methods to pinpoint interactions of the splicing machinery and RNA best suited for small molecule binding, designing and…”.
Tracked VC backing
No tracked VC backing recorded.
A portfolio listing documents backing; its observation date is not an investment date.
Dated public activity
· Form D filing
Reported sold as filed: $41,852,307 · Offering amount as filed: $130,107,279
SEC source checked 5 Nov 2026. Historical filing, not a current valuation.
View original evidence ↗
History is research context. Only qualifying milestones after your pick earn points.